셀루러티(CELU) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

CELU

Celularity Inc

7월 27일 4:00 PM ET (한국 7/28 05:00)

$0.75

+0.00 +0.13%

셀루러티(CELU) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$22M

스몰캡

P/E

배당수익률

없음

52주 위치

저점 +34% · 고점 -83%

애널리스트

매수

Fundamental health

vs. 방어주 초소형주· based on 2 axes

수익성

산출 불가 (적자)

성장

Top 42%

밸류에이션

데이터 부족

재무 안정

Top 92%

Index ⓘ	-	P/E ⓘ	-	EPS (ttm) ⓘ	-3.58	Insider Own ⓘ	46.06%	Shs Outstand ⓘ	28.8M	Perf Week ⓘ	-3.72%
Market Cap ⓘ	0.02B	Forward P/E ⓘ	-	EPS next Y ⓘ	-	Insider Trans ⓘ	-	Shs Float ⓘ	15.6M	Perf Month ⓘ	12.88%
Enterprise Value ⓘ	0.09B	PEG ⓘ	-	EPS next Q ⓘ	-	Inst Own ⓘ	7.51%	Short Float ⓘ	2.69%	Perf Quarter ⓘ	-32.34%
Income ⓘ	-0.09B	P/S ⓘ	0.82	EPS this Y ⓘ	-	Inst Trans ⓘ	-0.79%	Short Ratio ⓘ	2.7	Perf Half Y ⓘ	-41.78%
Sales ⓘ	0.03B	P/B ⓘ	-	EPS next 5Y ⓘ	-	ROA ⓘ	-29.73%	Short Interest ⓘ	0.42M	Perf YTD ⓘ	-32.34%
Book/sh ⓘ	-1.32	P/C ⓘ	3.52	EPS past 3/5Y ⓘ	- 49.85%	ROE ⓘ	-6367.24%	52W High ⓘ	-82.58% ($4.31)	Perf Year ⓘ	-74.63%
Cash/sh ⓘ	0.21	P/FCF ⓘ	-	Sales past 3/5Y ⓘ	13.88% 13.21%	ROIC ⓘ	-446.63%	52W Low ⓘ	34.08% ($0.56)	Perf 3Y ⓘ	-80.42%
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	-	EPS Y/Y TTM ⓘ	-35.2%	Gross Margin ⓘ	-3.08%	Volatility(W/M) ⓘ	6.11% 10.24%	Perf 5Y ⓘ	-99.1%
Dividend TTM ⓘ	-	EV/Sales ⓘ	3.4	Sales Y/Y TTM ⓘ	-51.03%	Oper. Margin ⓘ	-230.91%	ATR (14) ⓘ	0.07	Perf 10Y ⓘ	-
Dividend Ex-Date ⓘ	-	Quick Ratio ⓘ	0.15	EPS Q/Q ⓘ	-42.54%	Profit Margin ⓘ	-345.76%	RSI (14) ⓘ	48.34	Recom ⓘ	2
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	0.15	Sales Q/Q ⓘ	-77.37%	SMA20 ⓘ	2.58% ($0.73)	Beta ⓘ	0.5	Target Price ⓘ	$6
Payout ⓘ	-	Debt/Eq ⓘ	-	Earnings ⓘ	-	SMA50 ⓘ	-4.89% ($0.79)	Rel Volume ⓘ	0.24	Prev Close ⓘ	$0.75
Employees ⓘ	115	LT Debt/Eq ⓘ	-	EPS/Sales Surpr. ⓘ	-36% -	SMA200 ⓘ	-41% ($1.27)	Avg Volume(3M) ⓘ	0.16M	Price ⓘ	$0.75
IPO ⓘ	2019/8/8	Option/Short ⓘ	Yes/Yes			Trades ⓘ	225	Volume ⓘ	37,293	Change ⓘ	0.13%

Quarterly earnings trend SEC filings · USD

24.3

24.6

24.9

24.12*

25.3

25.6

25.9

25.12*

Revenue Net income 최근 분기: 매출 $4M (YoY -77%) · 순이익 $-24M (YoY -83%)

* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 Celularity Inc (CELU) Investment Analysis

What kind of company is Celularity Inc?

셀루러티(CELU) 방어주

Healthcare · Biotechnology

Small-Cap — Low Volume, High Volatility

🧬 This regenerative medicine company treats diabetic foot ulcers and tendon injuries using cells and biomaterials extracted from post-birth placentas. Building on revenue from its biobanking (umbilical cord storage) business, the company is working toward commercializing FDA 510(k)-cleared medical devices, including tendon lab products and bone fillers.

Learn more about Celularity Inc →

Market Cap

$0.0B

Approx. KRW 0.0 trillion

⚖️ 0% of Samsung Electronics

Market Cap Rank5234

Employees115people

IPO2019/08/08

Current Price$0.75 ≈ 1,028원

NASD · USA

Key Events

⏰ Upcoming events

🔔 Earnings release

The next release date has not been announced yet.

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2025년 11월 14일 (금) · 장 마감 후 EPS -36.0%

Is it profitable?

Both profitability & finances need caution

Review management risk carefully before investing

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

-230.9%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Net Margin

Share of revenue left after taxes and interest are paid

-345.8%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Gross Margin

Profit after subtracting raw-material costs only (signals product competitiveness)

-3.1%

✓ 평균

My positionMid-range

Low range Average High range

Biotechnology 초소형주 Median 53.4% · Bottom 25%

💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)

ROE

Annual return earned on shareholders' equity (15%+ is strong)

-6367.2%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROA

Annual earnings relative to total company assets

-29.7%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROIC

Return generated per dollar invested in the business

-446.6%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Financial health — Debt & liquidity burden

Current Ratio

Liquid assets available to cover liabilities due within a year

0.15

✓ 위험

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

0.15

✓ 위험

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook

Positive and negative signals are mixed

애널리스트 목표가

$6.00

현재가 대비 +700.0%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Volatility

Frequently misses analyst estimates

예상 상회

예상 부합

예상 하회

상회 비율

-36.0%

평균 서프라이즈

2025.11.14

하회

-36.0%

💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Average Growth

Mid-range within the industry

Healthy, Balanced Growth EPS and revenue are both growing steadily — a sustainable growth profile

📊 How much has it grown? (actual results)

Past 5-Year EPS

Actual average annual EPS growth over the past 5 years

+49.9%

우수

My positionTop 25%

Low range Average High range

방어주 초소형주 Median 16.4% · Top 21%

Past 5-Year Revenue

How much revenue grew over the past 5 years

+13.2%

우수

My positionTop 25%

Low range Average High range

방어주 초소형주 Median 2.1% · Top 18%

⚡ Short-term momentum

QoQ Revenue

Revenue change from the previous quarter (short-term momentum)

-77.4%

부진

My positionBottom 25%

Low range Average High range

방어주 초소형주 Median -4.5% · Bottom 13%

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -167%p below the market

CELU -99.1% · S&P 500 +68.3%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

-167.4%p

Significantly behind the market

vs Health Care (XLV)

-123.6%p

Significantly behind the sector average

1-year basis

vs S&P 500

-90.6%p

Significantly behind the market

vs Health Care (XLV)

-94.3%p

Significantly behind the sector average

Rank among peers

5-year return Lower-Mid (lower 28%) Based on 245 peers

1-year return Lower-Mid (lower 28%) Based on 315 peers

Current position within 52-week range

Low (-34.1%p) High (-82.6%p)

Current price is 34.1% above the 52-week low and 82.6% below the 52-week high

Recent risk (last 120 trading days)

Max drawdown

-59.5%

Annualized volatility

84.9%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🟢

Current diagnosis · 2026-07-27

Uptrend zone

Current price $0.75 above the midline ($0.73). Normal upward flow. Inside the Ichimoku cloud (neutral).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟡

Current diagnosis · 2026-07-27

Neutral zone — weak trend

MACD -0.002 · Signal -0.009 · Hist 0.007. Weak directional bias.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴

Current diagnosis · 2026-07-27

Bearish zone

RSI 48.1 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 30.8.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Cheaper than peers in its industry

Cheap on Vs. Sales

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

🧾 Vs. Sales Cheap

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

0.82x

✓ Very cheap

My positionTop 5%

Low range Average High range

Biotechnology 초소형주 median 11.24x · Top 1% — relatively cheap within the industry

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

Analyst target price (reference)

$6.00 vs. current price +700.0%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Biotechnology 초소형주

Who owns it?

Ownership flow shows some pressure

Institutional modest net selling -0.8% · Short interest light 2.7% · Short interest up +0.6pp over last 90d

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

0.0%

Insiders little change

🏦 Institutions (funds & investors)

-0.8%

Institutions net selling

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 7.5%

Retail-led

Healthcare 초소형주 Median 14.2%

🧑‍💼 Insiders 46.1%

Founder/management large holders (strong skin-in-the-game)

Healthcare 초소형주 Median 16.1%

👤 Retail investors (estimated) 46.4%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

2.7%

Low — limited short-side pressure

Healthcare 초소형주 Median 3.9%

Past 90 days 📈 +0.6%p increase

Short interest days to cover

2.7 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 28.8M주

Float (tradable shares) 15.6M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding CELU

ETFs with the highest weightings · 3 total shown

IWC

iShares Micro-Cap ETF

0.00%

$1.4B

VTI

Vanguard Total Stock Market ETF

0.00%

$657.4B

VXF

Vanguard Extended Market Index ETF

0.00%

$30.4B

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
CELU This Stock	$21.7M	-	-	-6367.24% ▼	-	+0.1%
LLY	$1.13T	43.1 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.1%
JNJ	$640.9B	30.8 ▼	7.5 ▼	25.74% ▲	2.02% ▲	+1.0%
ABBV	$453.9B	126.7 ▼	-	15221.82% ▲	2.67% ▲	-0.9%
UNH	$379.3B	26.9 ▼	3.9 ▼	12.49% ▲	2.16% ▲	-0.7%
MRK	$323.0B	36.8 ▼	7.0 ▼	18.97% ▲	2.5% ▲	-0.2%
Sector Avg	-	26.1	2.7	-48.83%	1.23%	-

FAQ

What kind of company is 셀루러티(CELU)?

셀루러티(CELU) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of CELU?

The market cap of CELU is approximately $22M, ranking 5,234 within its sector.

What is the 52-week high and low for CELU?

CELU has recorded a 52-week high of $4.31 and a low of $0.56.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.